Association between intracytoplasmic sperm injection and neurodevelopmental outcomes among offspring

Cheng-Wei Wang¹, Tzu-Hao Chang²,³*, Nai-Chen Chuang⁴, Heng-Kien Au⁵,⁶, Chi-Huang Chen¹,⁵, Sung-Hui Tseng⁷,⁸*

¹ Division of Reproduction Medicine, Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan, ² Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, ³ Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan, ⁴ Clinical Data Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan, ⁵ Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ⁶ Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan, ⁷ Department of Physical Medicine and Rehabilitation, Taipei Medical University Hospital, Taipei, Taiwan, ⁸ Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

* These authors contributed equally to this work.

D301091012@tmu.edu.tw

Abstract

Purpose

To compare the risk of neurodevelopmental disorders in children conceived via intracytoplasmic sperm injection (ICSI) and those conceived naturally.

Materials and methods

A population-based cohort study using data retrieved from the Taipei Medical University Research Database (TMURD) from January, 2004 to August, 2016. The data included maternal pregnancy history, perinatal history and developmental follow up of their babies up to 5 years of age. The study included 23885 children, of whom 23148 were naturally conceived and 737 were conceived via ICSI. Neurodevelopmental disorders defined by 21 ICD-9-CM codes.

Results

Of the 23885 children enrolled for analysis, 2778 children were included for further subgrouping analysis after propensity matching to reduce bias from maternal factors. The single-birth group included 1752 naturally conceived (NC) children and 438 ICSI children. The multiple-birth group included 294 NC and 294 ICSI children. The risk of neurodevelopmental disorders was not increased for ICSI children in both groups (single birth: adjusted hazard ratio aHR = 0.70, 95% CI = 0.39–1.27, \( p = 0.243 \); multiple-birth group aHR = 0.77, 95% CI = 0.43–1.35, \( p = 0.853 \)). In the single-birth group, multivariate analyses showed that male sex (aHR = 1.81, 95% CI = 1.29–2.54, \( p < 0.001 \)), and intensive care unit (ICU) admission (aHR = 3.10, 95% CI = 1.64–5.86, \( p < 0.001 \)) were risk factors for neurodevelopmental disorders.
In the multiple-birth group, multivariate analyses demonstrated that ICU admission (aHR = 3.58, 95% CI = 1.82–7.04, \( p < 0.001 \)), was risk factor for neurodevelopmental disorders.

Conclusion

Our study indicated that the use of ICSI does not associated with higher risk of neurodevelopmental disorders in the offspring. But male sex, and ICU admission do have increased risk of neurodevelopmental disorders. However, long term follow up of this cohort on health outcomes in adolescence and adulthood will strengthen the conclusions that ICSI is safe regarding offspring long term outcome.

Introduction

After the introduction of intracytoplasmic sperm injection (ICSI) in 1992, many infertility centers adopted this procedure as the primary fertilization method because ICSI has proven to be an effective method of fertilization [1]. It bypasses the selection process of natural sperm and is now frequently used in cases of male factor infertility, unexplained infertility, and failed fertilization. The percentage of assisted reproductive technology (ART) programs involving ICSI increased from 47.6% in 2000 to 66% in 2010 and is over 90% in some countries [2]. The increased popularity of ICSI raises questions about the health and development outcomes of ICSI children now and then as many studies offer inclusive results yet [3, 4]. Previous reports of ICSI have focused on neonatal physiological outcomes such as body weight, height, blood pressure, and congenital anomalies [5, 6]. Other studies have reported inconsistent results for neurodevelopmental sequelae in children conceived using ART including ICSI [7–10]. A recent systematic review reported inconclusive findings about the impact of ICSI on intelligence [11]. ICSI related technique, and process during critical window of epigenetic reprogramming has been one of the suggested mechanisms involved in the pathogenesis in a number of neurodevelopmental disorders in the offsprings [12]. These results suggest that the developmental aspects of ICSI-conceived children need more definite evidence.

In this study, our objective is to examine the association of ICSI by compare the risk of neurodevelopmental disorders in children conceived via ICSI and those conceived naturally based on Taipei Medical University Research Database (TMURD) which include the documentation of standardized health care process for ICSI, antenatal care, and development evaluation from 3 affiliated hospitals of Taipei Medical University.

Materials and methods

Data for the present study were retrieved Taipei Medical University Clinical Research Database (TMUCRD), which contains the electronic health records of more than 3 million patients from three affiliated teaching hospitals: Taipei Medical University Hospital (TMUH), Wan Fang Hospital (WFH), and Shuang Ho Hospital (SHH); patient profiles during the period January, 2004 to August, 2016 were used for patient enrollment. ICSI is done step by step, and each step has a billing code. Antenatal care of naturally conceived pregnancy also has well established timelines and billing codes in Taiwan. According to Children and Youth Welfare Law of Taiwan, children with developmental delay/disorders are those who have been evaluated by health ministry accredited multidisciplinary medical teams. Then the children will be eligible to receive early intervention services. Standardized health care process reduced risk of
misinterpretations and allows aggregate of data from different hospitals. All three hospitals have health ministry accredited multidisciplinary medical teams to perform developmental evaluation and assessment. This study was approved by the Institutional Review Board of Taipei Medical University (TMU-JIRB-201706049). The institutional research board of the TMU-JIRB approved the study and waived the requirement for informed consent and the further need of guidelines.

Inclusion criteria for the study included pregnant women who underwent a prenatal examination and gave birth between January, 2004 and August, 2016. Exclusion criteria included pregnant women who were under 20 years old, missing birth date of the newborn, misreported sex of pregnant woman, and non-ICSI patients. The included pregnant women were divided into an ICSI group and a natural-conception group. The ICSI group was defined as patients with ICSI and embryo transfer at least 300 days before childbirth. The non-ICSI group was defined as patients with embryo transfer at least 300 days before childbirth but without receiving ICSI. The natural-conception group was defined as patients without embryo transfer at least 300 days before childbirth.

Demographic data included maternal age, type of birth, maternal hospitalization history, maternal medication use, sex of newborn, gestation weeks, birth weight, neonatal intensive care unit (ICU) admission, and neonatal condition (ICD-9-CM 760–779). In this study, children with neurodevelopmental disorders were defined as those who had any of the following ICD-9-CM codes at least twice in EHR during the study period: brain hypoxia (ICD-9-CM 348), infantile cerebral palsy (ICD-9-CM 343), autism (ICD-9-CM 299), Attention-deficit/hyperactivity disorder (ADHD) (ICD-9-CM 314), intellectual disability (ICD-9-CM 317–319), developmental disabilities (ICD-9-CM 315), other speech disturbance (ICD-9-CM 7845), voice disturbance (ICD-9-CM 7844), aphasia (ICD-9-CM 7813), abnormality of gait (ICD-9-CM 7812), epilepsy (ICD-9-CM 345), blindness or low vision (ICD-9-CM 369), hearing loss (ICD-9-CM 389), anencephaly and similar anomalies (ICD-9-CM 740), chromosomal anomalies (ICD-9-CM 758), lack of expected normal physiological development in childhood (ICD-9-CM 7834), other developmental disorder (ICD-9-CM 783.9), other symbolic dysfunction (ICD-9-CM 7846), and special symptoms or syndromes not elsewhere classified (ICD-9-CM 307). Neonatal conditions identified by any of ICD-9 codes 760–779 in the perinatal period.

Descriptive statistics were used to summarize the demographic data. Continuous variables are presented as mean and standard deviation (SD), categorical variables are presented as the number of subjects and percentage (%). Propensity score matching (PSM) was used to reduce bias from maternal factors, including maternal age, maternal hospitalization history, and maternal medication use. Before PSM, Student’s t test was used to assess maternal age, gestation weeks, and birth weight; and the chi-squared test or Fisher’s exact test were used for type of birth, maternal hospitalization history, maternal medication use, sex of newborn, ICU admission, and neonatal condition. Subgroup analysis was used to determine the risk factors for developmental disabilities in the single-birth and multiple-birth groups. After PSM, the differences between matched pairs were evaluated using the signed rank test for continuous data and McNemar’s test for binary data. Cox proportional hazards regression was used to determine the risk factors for developmental disabilities by including all the candidate variables in the model. A two-sided statistical test at 5% significance was used. All of the analyses were performed using SAS Enterprise Guide software version 7.11 (SAS Institute, Cary, NC, USA).

**Results**

We performed a chart review for 19,382 pregnant women underwent a prenatal examination and gave birth in TMUH, WFH, and SHH during the study period. After removing the data
for individuals who met the exclusion criteria, 23,885 newborns were enrolled in the study, including 22,786 singleton babies and 1,099 multiple-birth babies (Fig 1). The mean follow-up time was 3.3 ± 2.3 years. The baseline characteristics of the pregnant women and their newborns included in the study are shown in Table 1. The maternal age was significantly higher in the ICSI group than in the natural-conception group (36.5 ± 3.7 years vs 32.0 ± 4.6 years, \( p < 0.001 \)). In contrast, birth weeks and birth weights were significantly lower in the ICSI
group than in the natural-conception group (36.6 ± 3.0 weeks vs 38.5 ± 1.8 weeks, \( p < 0.001 \); 2639.8 ± 679.0 g vs 3092.5 ± 477.8 g, \( p < 0.001 \), respectively). The proportions of multiple births, maternal medication use, and ICU admissions were significantly higher in the ICSI group than in the natural-conception group (all \( p < 0.001 \)). In contrast, the proportion of male babies was significantly lower in the ICSI group than in the natural-conception group (47.6% vs 51.7%, \( p = 0.033 \)).

Subgroup analysis was used to determine the risk factors for neurodevelopmental disorders separately in single-birth and multiple-birth groups. In the single-birth group, 22,345 naturally conceived babies and 441 ICSI babies were included (Fig 1), and the maternal age was significantly higher for the ICSI babies than for the naturally conceived babies (36.9 ± 3.6 years vs 32.0 ± 4.5 years, \( p < 0.001 \)). In contrast, gestation weeks (38.0 ± 2.3 weeks vs 38.6 ± 1.7 weeks, \( p < 0.001 \)) and birth weight (2984.4 ± 553.2 g vs 3119.5 ± 455.1 g, \( p < 0.001 \)) were still significantly lower for the ICSI babies than for the naturally conceived babies. The proportions of maternal medication use (4.8% vs 1.5%, \( p < 0.001 \)) and neonatal ICU admission (6.8% vs 2.6%, \( p < 0.001 \)) were significantly higher in the ICSI group than in the natural-conception group (45.8% vs 51.8%, \( p = 0.014 \)) (Table 2). To reduce selection bias, 1:4 PSM was used to match the characteristics of the pregnant women, such as maternal age, maternal hospitalization history, and maternal medication use, in the single-birth group. After PSM, the final analyses included 1,752 naturally conceived babies and 438 ICSI babies (Fig 1). Table 3 shows that none of the characteristics of the pregnant women differed significantly between the natural-conception and ICSI groups. The trends for the other variables were similar to those before matching.

The multiple-birth group included 803 naturally conceived babies and 296 ICSI babies (Fig 1). The trends for all of the variables in the multiple-birth group were similar to those for the single-birth group, except for maternal hospitalization history, maternal medication use, the
sex of the newborn, and neonatal condition (Table 2). The proportion of mothers with a history of hospitalization was significantly lower in the ICSI group than in the natural-conception group (2.7% vs 8.0%, \( p = 0.001 \)). Rates of maternal medication use and the sex of the newborn baby did not differ significantly between the two groups. Rate of neonatal condition was significantly higher in the ICSI group than in the natural-conception group (76.7% vs 70.4%, Table 2). After 1:1 PSM was used to match the characteristics of the pregnant women in the

### Table 2. Characteristics of pregnant women and newborns for patients with single and multiple births.

|                        | Single birth | Multiple births |
|------------------------|--------------|-----------------|
|                        | Total (n = 22,786) | Naturally conceived (n = 22,345) | ICSI (n = 441) | Total (n = 1,009) | Naturally conceived (n = 803) | ICSI (n = 296) |
| Maternal age (years)   | 32.1 ± 4.6 | 32.0 ± 4.5 | 36.9 ± 3.6 | <0.001 | 34.1 ± 4.3 | 33.4 ± 4.4 | 35.9 ± 3.7 | <0.001 |
| Maternal hospitalization history | 768 (3.4) | 759 (3.4) | 9 (2.0) | 0.141 | 72 (6.6) | 64 (8.0) | 8 (2.7) | 0.001 |
| Maternal medication use | 363 (1.6) | 342 (1.5) | 21 (4.8) | <0.001 | 18 (1.6) | 12 (1.5) | 6 (2.0) | 0.593 |
| Sex of newborn, male   | 11773 (51.7) | 11571 (51.8) | 202 (45.8) | 0.014 | 538 (49.0) | 389 (48.4) | 149 (50.3) | 0.587 |
| Gestation weeks        | 38.6 ± 1.7 | 38.6 ± 1.7 | 38.0 ± 2.3 | <0.001 | 35.4 ± 2.5 | 35.7 ± 2.4 | 34.5 ± 2.7 | <0.001 |
| Birth weight           | 3116.8 ± 457.5 | 3119.5 ± 455.1 | 2984.4 ± 553.2 | <0.001 | 2279.3 ± 496.6 | 2336.9 ± 483.0 | 2124.6 ± 500.1 | <0.001 |
| ICU admission          | 620 (2.7) | 590 (2.6) | 30 (6.8) | <0.001 | 179 (16.3) | 104 (13.0) | 75 (25.3) | <0.001 |
| Neonatal condition     | 14621 (64.2) | 14353 (64.2) | 268 (60.8) | 0.133 | 792 (72.1) | 565 (70.4) | 227 (76.7) | 0.041 |

Data period: 2004/01/01-2016/08/31.

ICSI, Intracytoplasmic sperm injection; ICU, intensive care unit.
Continuous variables are presented as mean and standard deviation (SD); categorical variables are presented as the number of subjects and percentage (%).

### Table 3. Matched characteristics of pregnant women and newborns for patients with single and multiple births.

|                        | Single birth | Multiple births |
|------------------------|--------------|-----------------|
|                        | Total (n = 2,190) | Naturally conceived* (n = 1,752) | ICSI* (n = 438) | Total (n = 588) | Naturally conceived* (n = 294) | ICSI* (n = 294) |
| Maternal age (years)   | 36.8 ± 3.5 | 36.8 ± 3.5 | 36.8 ± 3.5 | 0.969 | 35.8 ± 3.6 | 35.8 ± 3.7 | 35.8 ± 3.6 | 0.929 |
| Maternal hospitalization history | 34 (1.6) | 25 (1.4) | 9 (2.1) | 0.385 | 16 (2.7) | 8 (2.7) | 8 (2.7) | 1.000 |
| Maternal medication use | 97 (4.4) | 78 (4.5) | 19 (4.3) | 0.917 | 14 (2.4) | 8 (2.7) | 6 (2.0) | 0.788 |
| Sex of newborn, male   | 1145 (52.3) | 945 (53.9) | 200 (45.7) | **0.002** | 293 (49.8) | 145 (49.3) | 148 (50.3) | 0.869 |
| Gestation weeks        | 38.3 ± 2.1 | 38.4 ± 2.0 | 38.0 ± 2.4 | **0.002** | 35.2 ± 2.5 | 35.8 ± 2.1 | 34.5 ± 2.7 | **<0.001** |
| Birth weight, g        | 3096.5 ± 516.8 | 3125.3 ± 503.2 | 2982.5 ± 553.6 | **<0.001** | 2231.0 ± 495.3 | 2341.5 ± 466.6 | 2121.3 ± 499.3 | **<0.001** |
| ICU admission          | 95 (4.3) | 65 (3.7) | 30 (6.8) | **0.006** | 116 (19.7) | 41 (13.9) | 75 (25.5) | 0.001 |
| Neonatal condition     | 1375 (62.8) | 1110 (63.4) | 265 (60.5) | 0.270 | 415 (70.6) | 189 (64.3) | 226 (76.9) | 0.001 |

Data period: 2004/01/01-2016/08/31.

ICSI, Intracytoplasmic sperm injection; ICU, intensive care unit.
Continuous variables are presented as mean and standard deviation (SD); categorical variables are presented as the number of subjects and percentage (%).

* The results were performed by 1:4/1:1 propensity score matching on single/ multiple births patients, matching variables included maternal age, maternal hospitalization history, and maternal medication use. The differences between matched pairs were evaluated using the signed rank test for continuous data and the McNemar’s test for binary data.

Boldface indicates a significant difference (\( p < 0.05 \)).

https://doi.org/10.1371/journal.pone.0257268.t002

https://doi.org/10.1371/journal.pone.0257268.t003
multiple-birth group, 294 naturally conceived babies and 294 ICSI babies were included (Fig 1). Table 3 shows that the results for gestation weeks, birth weight, ICU admissions, and the neonatal condition were similar to those before matching.

The outcome of the Cox proportional hazards regression analysis is summarized in Fig 2. In the single-birth group, the univariate and multivariate analyses both demonstrated that male sex (hazard ratio [HR] = 1.89, 95% confidence interval [CI] = 1.35–2.62, \( p < 0.001 \); adjusted HR [aHR] = 1.81, 95% CI = 1.29–2.44, \( p < 0.001 \)) and ICU admission (HR = 3.65, 95% CI = 2.17–6.14, \( p < 0.001 \); aHR = 3.10, 95% CI = 1.64–5.86, \( p < 0.001 \)) were risk factors for neurodevelopmental disorders. However, although gestation weeks was associated with a significantly lower risk in the univariate model, the significance disappeared in the multivariate analysis (HR = 0.94, 95% CI = 0.89–0.99, \( p = 0.011 \); aHR = 1.00, 95% CI = 0.91–1.10, \( p = 0.966 \)). In the multiple-birth group, the univariate and multivariate analyses both indicated that ICU admission (HR = 5.28, 95% CI = 3.12–8.94, \( p < 0.001 \); aHR = 3.58, 95% CI = 1.82–7.04, \( p < 0.001 \)) was risk factors for neurodevelopmental disorders. However, gestation weeks and birth weight were associated with a significantly lower risk in univariate analysis but not in multivariate analysis. The neonatal condition was associated with a significantly higher risk in univariate analysis but not in multivariate analysis (HR = 2.79, 95% CI = 1.38–5.64, \( p = 0.004 \); aHR = 1.81, 95% CI = 0.86–3.80, \( p = 0.116 \)). After adjusting for all variables, the ICSI group does not increase the risk of neurodevelopmental disorders compared with the natural-conception group in both single- and multiple-birth groups (aHR = 0.70, 95% CI = 0.39–1.27, \( p = 0.243 \); aHR = 0.77, 95% CI = 0.43–1.35, \( p = 0.853 \), respectively).

| Without neoneurodevelopmental disorders | With neoneurodevelopmental disorders | Univariate | Multivariate* |
|----------------------------------------|--------------------------------------|------------|---------------|
| Without natural conception | n = 294 | 0.347 | 0.243 |
| With natural conception | n = 294 | 1 | 1 |
| Male | 149 (48.5) | 0.76 (0.42, 1.35) | 0.42 (0.21, 0.82) |
| Female | 145 (49.3) | 0.70 (0.39, 1.27) | 0.70 (0.39, 1.27) |
| Gestation weeks | 38 (12.9) | 0.948 (0.80, 1.10) | 0.948 (0.80, 1.10) |
| Birth weight | 0.014 | 1.00 (0.99, 1.00) | 1.00 (0.99, 1.00) |
| ICU admission | 0.001 | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) |
| Neonatal condition | 0.012 | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) |

*Model included all variables, such as ICSI group, sex of newborn, birth gestation weeks, birth weight, ICU admission, and neonatal condition.

**Table 3.** Univariate and multivariate cox regression analysis of neurodevelopmental disorders in subgroup analysis.

https://doi.org/10.1371/journal.pone.0257268.g002

Fig 2. Univariate and multivariate cox regression analysis of neurodevelopmental disorders in subgroup analysis.
Discussion

In this cohort study, we compared neurodevelopmental consequences of the children born after ICSI with those conceived naturally by analyzing both maternal and offspring factors. The ICSI mothers were older (36.5 years vs 32.2 years, \( p < 0.001 \)) and had a higher rate of medication use (3.7% vs 1.6%, \( p = 0.001 \)) (Tables 1 and 2). ICSI had significantly higher rates of multiple live births, preterm birth, low birth weight, and ICU admission. The results are in line with the previous studies that women enter infertility programs at an older age, and ART procedures generally result in a higher rate of multiple pregnancies [13]. In addition, ICSI mothers may use more medication than natural-conception mothers for two reasons: first, ART requires luteal support up to at least 8 weeks of gestation, and second, obstetrical complications increase with increasing maternal age and multiple pregnancies, as seen in the ICSI group.

In this study, neonatal conditions are identified by any of ICD-9 codes 760–779 in the perinatal period, which include conditions not severe. This may be the reason that in multivariate analysis, the neonatal condition only showed trend of increased association with neurodevelopmental disorders (aHR = 1.81, 95% CI = 0.86–3.80, \( p = 0.116 \)). However, ICU admission appears to be a significant risk factor for neurodevelopmental disorders (HR = 3.65, 95% CI = 2.17–6.14, \( p < 0.001 \); aHR = 3.10, 95% CI = 1.64–5.86, \( p < 0.001 \)), after we matched for maternal conditions and performed univariate and multivariate regression analysis. The result suggests that as the neonatal ICU admission means that the baby has more serious etiologic indications for admission which impact the development of the babies born after ICSI or spontaneous conception [14]. Therefore, early and regular developmental surveillance and assessment are warranted in this group of children.

Our results are in line with other studies that ICSI and naturally conceived children have comparable risks of developmental disabilities [15, 16]. In genomic era, more studies have reported de novo mutations as the cause of developmental disorders such as autism and intellectual disabilities [17, 18]. Germline de novo mutation has been associated with increased paternal age at conception [19]. In ICSI, a single sperm is selected and injected directly into an oocyte to complete fertilization, while natural conception involves the natural selection of competent sperm. The procedure probably reduced the so called paternal age effect.

Many factors undermine poor child development [20]. The strength of this study is that we investigated the causality of ICSI offspring development outcome by matching obstetric factors and neonatal factors. But one of the limitations of this study is that we did not include paternal age factor in our analysis. Although in the present study we matched for some maternal factors, other maternal factors, such as preeclampsia [21], uterine myoma [22], adenomyosis [23], and socioeconomic factors, could have contributed to preterm labor and ICU admission [24]. To ensure the accuracy of the diagnosis of neurodevelopmental disorders, we used patients for whom the same disease code appeared more than twice in the database. Patients with a single coded visit were not included, which may have excluded some part of a potential diseased population. Therefore, the sample size of the developmental disability group in this study was relatively small compared with the normal group. In addition, because the average follow-up period in this study was 3 to 5 years, the development outcomes after 5 years old are unknown.

In conclusion, this study makes an important contribution to the body of evidence concerning the association of neurodevelopmental disorders with ICSI. The findings suggest that ICSI is not associated with increased risk of neurodevelopmental disorders, while male sex, and ICU admission increase the risk of neurodevelopmental disorders in both single and multiple births. However, studies with larger sample sizes and longer follow up are needed to confirm these findings.
Acknowledgments

The authors acknowledge the statistical support of the Clinical Data Center, Office of Data Science, Taipei Medical University, Taiwan.

Author Contributions

Conceptualization: Cheng-Wei Wang, Tzu-Hao Chang, Sung-Hui Tseng.

Formal analysis: Nai-Chen Chuang.

Methodology: Nai-Chen Chuang.

Writing – original draft: Cheng-Wei Wang, Tzu-Hao Chang, Nai-Chen Chuang, Heng-Kien Au, Chi-Huang Chen, Sung-Hui Tseng.

Writing – review & editing: Cheng-Wei Wang, Tzu-Hao Chang, Nai-Chen Chuang, Heng-Kien Au, Chi-Huang Chen, Sung-Hui Tseng.

References

1. Palermo G., Joris H., Devroye P. & Van Steirteghem A. C. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 340, 17–18 (1992). https://doi.org/10.1016/0140-6736(92)92495-5 PMID: 1530078

2. Dyer S. et al. International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2008, 2009 and 2010. Hum. Reprod. 31, 1588–1609 (2016). https://doi.org/10.1093/humrep/dev082 PMID: 27207175

3. Rumbold A. R. et al. Impact of male factor infertility on offspring health and development. Fertility and sterility 111, 1047–1053 (2019). https://doi.org/10.1010/j.fertnstert.2019.05.006 PMID: 31155114

4. Niederberger C. Re: Impact of Male Factor Infertility on Offspring Health and Development. The Journal of Urology 203, 451–451 (2020). https://doi.org/10.1097/JU.0000000000000969.04 PMID: 31829814

5. Hart R. & Norman R. J. The longer-term health outcomes for children born as a result of IVF treatment: Part I—General health outcomes. Hum. Reprod. Update 19, 232–243 (2013). https://doi.org/10.1093/humupd/dms062 PMID: 23449642

6. Hart R. & Norman R. J. The longer-term health outcomes for children born as a result of IVF treatment. Part II—Mental health and development outcomes. Hum. Reprod. Update 19, 244–250 (2013). https://doi.org/10.1093/humupd/dmt002 PMID: 23449643

7. Kissin D. M. et al. Association of assisted reproductive technology (ART) treatment and parental infertility diagnosis with autism in ART-conceived children. Hum. Reprod. 30, 454–465 (2015). https://doi.org/10.1093/humrep/deu338 PMID: 25518976

8. Bay B., Mortensen E. L. & Kesmodel U. S. Fertility treatment and child intelligence, attention, and executive functions in 5-year-old singletons: a cohort study. BJOG 121, 1642–1651 (2014). https://doi.org/10.1111/1471-0528.12907 PMID: 24910885

9. Knoester M. et al. Cognitive development of singletons born after intracytoplasmic sperm injection compared with in vitro fertilization and natural conception. Fertility and sterility 90, 289–296 (2008). https://doi.org/10.1010/j.fertnstert.2007.06.090 PMID: 17980875

10. Sandin S., Nygren K.-G., Iliadou A., Hultman C. M. & Reichenberg A. Autism and mental retardation among offspring born after in vitro fertilization. JAMA 310, 75–84 (2013). https://doi.org/10.1001/jama.2013.7222 PMID: 23821091

11. Rumbold A. R. et al. The impact of specific fertility treatments on cognitive development in childhood and adolescence: a systematic review. Hum. Reprod. 32, 1489–1507 (2017). https://doi.org/10.1093/humrep/dex085 PMID: 28472417

12. La Rovere M. et al. Epigenetics and Neurodevelopmental Disorders in ART. Int J Mol Sci. 20, 4169 (2019). https://doi.org/10.3390/ijms20174169 PMID: 31454921

13. Qin J. et al. Pregnancy-related complications and adverse pregnancy outcomes in multiple pregnancies resulting from assisted reproductive technology: a meta-analysis of cohort studies. Fertility and sterility 103, 1492–508.e1–7 (2015). https://doi.org/10.1010/j.fertnstert.2015.03.018 PMID: 25910567

14. Pascal A. et al. Neurodevelopmental outcome in very preterm and very-low-birthweight infants born over the past decade: a meta-analytic review. Dev Med Child Neurol 60, 342–355 (2018). https://doi.org/10.1111/dmcn.13675 PMID: 29350401
15. Liapi S. & Polychronopoulou S. Cognitive and socio-emotional development and manifestation of learning disabilities of 8- to 10-year-old children born after intracytoplasmic sperm injection compared to naturally conceived children. *Clin Exp Obstet Gynecol* 44, 104–109 (2017). PMID: 29714876

16. Sutcliffe A. G. et al. A retrospective case-control study of developmental and other outcomes in a cohort of Australian children conceived by intracytoplasmic sperm injection compared with a similar group in the United Kingdom. *Fertility and sterility* 79, 512–516 (2003). https://doi.org/10.1016/s0015-0282(02)04701-5 PMID: 12620432

17. Alonso-Gonzalez A., Rodriguez-Fontenla C. & Carracedo A. De novo Mutations (DNMs) in Autism Spectrum Disorder (ASD): Pathway and Network Analysis. *Front Genet* 9, 406 (2018). https://doi.org/10.3389/fgene.2018.00406 PMID: 30298087

18. Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* 542, 433–438 (2017). https://doi.org/10.1038/nature21062 PMID: 28135719

19. Goldmann J. M., Veltman J. A. & Gilissen C. De Novo Mutations Reflect Development and Aging of the Human Germline. *Trends Genet.* 35, 828–839 (2019). https://doi.org/10.1016/j.tig.2019.08.005 PMID: 31610893

20. Donald K. A. et al. Risk and protective factors for child development: An observational South African birth cohort. *PLoS Med.* 16, e1002920 (2019). https://doi.org/10.1371/journal.pmed.1002920 PMID: 31560687

21. Cheng S.-W., Chou H.-C., Tsou K.-I., Fang L.-J. & Tsao P.-N. Delivery before 32 weeks of gestation for maternal pre-eclampsia: neonatal outcome and 2-year developmental outcome. *Early Hum. Dev.* 76, 39–46 (2004). https://doi.org/10.1016/j.earhumdev.2003.10.004 PMID: 14729161

22. Chen Y.-H., Lin H.-C., Chen S.-F. & Lin H.-C. Increased risk of preterm births among women with uterine leiomyoma: a nationwide population-based study. *Hum. Reprod.* 24, 3049–3056 (2009). https://doi.org/10.1093/humrep/dep320 PMID: 19740897

23. Juang C.-M. et al. Adenomyosis and risk of preterm delivery. *BJOG* 114, 165–169 (2007). https://doi.org/10.1111/j.1471-0528.2006.01186.x PMID: 17169011

24. Pinares-Garcia P., Stratikopoulos M., Zagato A., Loke H. & Lee J. Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders. *Brain Sci* 8, 154 (2018). https://doi.org/10.3390/brainsci8080154 PMID: 30104506